Skip to content

Alamar Biosciences

US · ALMR #2657 by market cap Listed 2026
26.48 -2.20 -7.67%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Financial Health how this is computed

Fair
  • Altman Z-Score is 2.40, in the 1.8-3.0 "grey zone".
  • Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.

✦ Quant Revenue Concentration how this is computed

Lead segment, long tail
  • Consumables is the largest reported line at 53.16% of revenue, across 3 reported segments.
  • Instruments follows at 25.24%, so the top line still matters most but isn’t the whole story.

Revenue annual, last 2 years

Latest year +195.17% YoY

Margins

Gross margin
56.20%
Operating margin
-42.22%
Net margin
-40.18%

Key ratios & quality

Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.

Income statement

Line item 2024 2025
Revenue 25.14M74.21M
Gross profit 8.61M41.71M
Selling & admin expenses 18.94M35.57M
Research & development 39.23M37.47M
Operating profit -49.57M-31.33M
Pretax profit -47.06M-29.15M
Tax 13.00K665.00K
Net profit -47.07M-29.82M
Basic EPS -10
Diluted EPS -0.71-0.45

Balance sheet

Line item 2024 2025
Total current assets 106.70M94.71M
Cash & ST investments 79.36M30.00M
Inventory 14.41M38.48M
Total assets 149.51M139.99M
Total current liabilities 16.59M23.73M
Short-term debt 1.91M2.10M
Long-term debt --9.81M
Total liabilities 282,922,000.00298,946,000.00
Total equity -133.41M-158.95M
Retained earnings -138.96M-168.78M

Cash flow

Line item 2024 2025
Operating cash flow -55.21M-53.61M
Depreciation & amortization 3.19M3.86M
Free cash flow -58.60M-59.99M
Dividends paid ----
Stock buybacks / issuance 940.00K1.49M
Ending cash balance 31.68M34.91M

Returns & efficiency

Line item 2024 2025
ROE % ----
ROA % -31.48-20.60
ROIC % ----
5-year avg ROE % ----
EBIT margin % -178.91-38.74
FCF / sales % ----
Current ratio 6.433.99
Quick ratio 5.221.80
Debt / assets 22.1429.63
LT debt / equity ----
Interest coverage -21.65-71.70
Revenue CAGR (3Y) % ----
Net income CAGR (3Y) % ----
FCF CAGR (3Y) % ----

Revenue breakdown most recent period

Business

Consumables53.16%
Instruments25.24%
Services21.60%

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Alamar Biosciences discussion 0 comments

Add a comment